Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study* - 01/09/11
Abstract |
Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5% cream for sBCC to find the most effective frequency of dosing with tolerable side effects. Methods: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. Results: Complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. Conclusion: Imiquimod 5% cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles. (J Am Acad Dermatol 2002;47:390-8.)
Le texte complet de cet article est disponible en PDF.Plan
 | *A list of all enrolling investigators can be found at the end of the article. |
| Sponsored by 3M Pharmaceuticals, St. Paul, Minn. Drs Geisse, Rich, Pandya, and Gross have received support from 3M Pharmaceuticals for performing clinical trials. Drs Geisse and Rich have served as consultants for 3M Pharmaceuticals. Drs Pandya and Gross have received honoraria for participation in a speaker's bureau. Dr Owens and Ms Andres are employees of 3M Pharmaceuticals, and Ms Ginkel is a former employee. |
 | Reprint requests: John K. Geisse, MD, Solano Dermatology Associates, 127 Hospital Dr, Suite 204, Vallejo, CA 94589. |
Vol 47 - N° 3
P. 390-398 - septembre 2002 Retour au numéro
Article précédent
- Pityriasis rubra pilaris in children
- Dawn S. Allison, Rokea A. el-Azhary, Stella D. Calobrisi, Charles H. Dicken
- Efficacy of a low-dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial
- James Leyden, Alan Shalita, Maria Hordinsky, Leonard Swinyer, Frank Z. Stanczyk, Margaret E. Weber
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?